Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

Bispecific Antibodies in the Lymphoma Outpatient Setting Ashley Staton, MD Bone Marrow Transplant Physician Ochsner Medical Center March 31 ,2023 Disclosures None Most Common Subtypes of Non Hodgkin Lymphoma What is a BiSpecific T Cell Engager (BiTEs) • Concept first appeared in the early 1960s • First example constructed in 1985 • BiTEs activate …
aTTP/iTTP: Clinical Approach and recent updates Maissaa Janbain, MD, MSCR Tulane School of Medicine Disclosures • Advisory Committee: Takeda • Honoraria: Takeda, Bayer, Genentech, Biomarin, CSL Behring, Spark Therapeutics, Octapharma, Sanofi, Sobi • Speaker Bureau: Takeda, Biomarin, Spark therapeutics, CSL Behring, Sanofi • Research support: Genentech Agenda …
Virginia Association of Hematology - Oncology Membership Conference May 11-13, 2023 The Founders Inn, Virginia Beach, VA Agenda Thursday, May 11 6:30 pm Networking Reception with Exhibitors (*All are welcome) Friday, May 12 7:30 am Registration, Breakfast & Resource Center 8:25 am Welcome & Introductions Richard Ingram, MD President, Virginia …
With Dr. Barbara Schmidtman's blog this month, she hopes to remind you (and your teams) that simple things like taking a time out, going on quick walk, and more can help you with self-care during the workday.
Updated 4-17-23
The U.S. population is aging. So ACCC—in partnership with the Institute for Healthcare Improvement (IHI)—developed the Oncology Action Community to help participating cancer programs and practices become age-friendly health systems.
MSCO 2023 Spring Conference Wednesday, April 19 6:00 – 9:00 PM CDT Agenda 6:00 PM Registration/Networking Reception/Fellow & Resident Posters 7:00 PM Welcome and Introductions Amrit Singh, MD President Minnesota Society of Clinical Oncology 7:05 PM Neoadjuvant and Adjuvant Immunotherapy for Lung Cancer Patrick Forde, M.B.B.Ch. Co-Director, Division of Upper Aerodigestive …
An Innovative Approach to Navigating Patients Through Cancer Diagnostics ASSOCIATION OF COMMUNITY CANCER CENTERS P recision medicine is all about the details. It is stepping away from a one-size-fits-all approach for cancer diag-nostics and when implemented correctly, ensures each patient has access to the most appropriate biomarker testing and associated treatment options. …
March 24, 2023
In the third webinar, we will hear from Jennifer Paquet, RN, BSN, Financial Assistance Patient Care Coordinator Supervisor from Bassett Cancer Institute and Aimee Hoch, MSW, LSW, Oncology Financial Navigator from Grand View Health Cancer Center. We will discuss barriers to radiology prior authorizations and provide insights on how to address them.
Sagar Sardesai, MD MPH Associate Professor, Medical Oncology Medical Director, High Risk Breast Program March 24th, 2023 An Update on Medical Management of High-Risk Women Disclosures ▪ Consultant ▪ Immunomedics ▪ Novartis ▪ Biotheranostic ▪ Gilead ▪ Research Support ▪ AstraZeneca ▪ Immunomedics ▪ Gilead ▪ Senhwa Biosciences ▪ I will be discussing …
First Case of Acquired EGFR C797S Mutation Rendering Resistance to Osimertinib, followed by a near complete response with first generation EGFR TKI in a patient with EGFR mutated NSCLC Jared Reed MD PGY-2 Internal Medicine Resident Marshall University/Edwards Comprehensive Cancer Center Disclosure of Conflicts of Interest • Jared Reed, MD, has no relevant financial …
PowerPoint Presentation Borna Amir-Kabirian, MD PGY2 Internal Medicine Resident Charleston Area Medical Center The Incidence of Venous Thromboembolisms in Pregnancy with Known Cannabis Use DISCLOSURE OF CONFLICTS OF INTEREST • Borna Amir-Kabirian, MD, has no financial relationships to disclose. ACKNOWLEDGEMENTS • Amir Kamran, MD Department of …
Prevalence of UGT1A1 polymorphisms in gastrointestinal cancer: A single-institutional retrospective study Bei Jiang, MD, PhD Hematology and Oncology fellow West Virginia University Disclosure of Conflicts of Interest Bei Jiang, MD, PhD, has no relevant financial relationships to disclose. UGT1A1 polymorphisms conferring increased risk of irinotecan related …
Opportunities to Engage with the NCI Community Oncology Research Program (NCORP) Ann M. Geiger, MPH, PhD Scienti f ic Di rec tor, Cancer Care Del ivery Research, NCORP Heal thcare Del ivery Research Program NCI Div is ion of Cancer Contro l and Population Sc ience 2 Disclosures ▪ None. 3 Topics 1. Context 2. NCI-Supported Trials Networks 3. …
March 24, 2023
The evolving oncology landscape is requiring oncology practices to implement new and innovative approaches for improving care delivery. Experience a collaborative forum that unites leading experts from across the state to explore clinical advances in the pipeline, nuances of new and existing treatments, and the impact of national policies on state-level initiatives. If you are employed by a …
New Molecular Entities • None Changes in Labeled Indications • Opdivo® (nivolumab) and Yervoy® (ipilimumab) – FDA expanded the already approved indication for use of the two IO agents in combination to treat adult patients with unresectable or metastatic melanoma to now include use in treating pediatric patients 12 years of age or older. • Trodelvy® (sacituzumab …
ACCC held a LinkedIn live event on March 13, 2023, with subject matter experts, who shared strategies for tackling lung cancer disparities in the Appalachian Region and beyond.
Annual Meeting Saturday, April 29, 2023 Hutton Hotel Friday, April 28 Welcome Reception Saturday, April 29 7:00 AM Registration/Networking Breakfast 8:00 AM Welcome & Introductions Richard L. Martin, III, MD President, TOPS 8:15 AM Practical Guide to Building Community Research Program David Spigel, MD Tennessee Oncology …
March 22, 2023
In the second webinar, we will hear from Andre D. Harvin, PharmD, MS, Executive Director of Pharmacy for Oncology at Cone Health. We will discuss how your pharmacy team can be a major ally and support in obtaining prior authorizations, help navigate biosimilar changes, and address medical necessity.